Clinical Trial Update: T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs [Phase 1]

View source ↗

Summary

A Phase 1 trial of autologous CD4+CD127lo/-CD25+ polyclonal regulatory T cells for Type 1 diabetes mellitus has completed, with results posted in July 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Regulatory T cells (CD4+CD127lo/-CD25+ polyclonal) (CD4+CD127lo/-CD25+ polyclonal regulatory T cells)

Snippet

Sponsor: University of California, San Francisco | Conditions: Type 1 Diabetes Mellitus | Phase 1 | Status: COMPLETED | Results posted: 2018-07-11